NexPoint Life Sciences DST — Form D/A

NexPoint Life Sciences DST of DALLAS, TX, a company, filed a Form D amendment with the SEC on 2022-01-04. The offering totals $107.6M, of which $5.3M was reported sold. Industry: Other Real Estate.

Offering

Filed: 2022-01-04
Form: D/A
Accession: 0001901493-22-000001
Industry: Other Real Estate
Exemptions: 06b
Total offering: $107.6M
Amount sold: $5.3M
Remaining: $102.3M
Minimum investment: $100K
Investors: 8
Date of first sale: 2021-12-16
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-426919

Issuer

Name: NexPoint Life Sciences DST
CIK: 0001901493
Entity type: Other
Jurisdiction: DELAWARE
Incorporated: 2021
Address: 300 CRESCENT COURT, DALLAS, TX, 75201
Phone: (833) 697-6246

Officers, directors & promoters (5)

Name	Role	Location
Matt McGraner	Executive Officer	Dallas, TX
N/A NexPoint Real Estate Advisors IV, L.P.	Executive Officer	Dallas, TX
Matthew Goetz	Executive Officer	Dallas, TX
N/A NREA Casper, LLC	Executive Officer	Dallas, TX
N/A NREA Casper Investment Co, LLC	Executive Officer	Dallas, TX

Other filings by this issuer (13)

Filed	Form	Offering	Sold
2022-06-06	D/A	$107.6M	$105.0M
2022-05-24	D/A	$107.6M	$104.5M
2022-05-10	D/A	$107.6M	$104.3M
2022-04-26	D/A	$107.6M	$102.2M
2022-04-19	D/A	$107.6M	$97.8M
2022-04-05	D/A	$107.6M	$89.0M
2022-03-22	D/A	$107.6M	$81.8M
2022-03-08	D/A	$107.6M	$67.9M
2022-02-23	D/A	$107.6M	$39.9M
2022-02-10	D/A	$107.6M	$35.0M
2022-01-26	D/A	$107.6M	$24.2M
2022-01-18	D/A	$107.6M	$12.8M
2021-12-28	D	$107.6M	$5.2M

More